Selected research
Industry Research
Mumps Drug Industry Research Report 2026
Market perspective
The global Mumps Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Mumps Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Mumps Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Mumps Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Mumps Drug include GlaxoSmithKline Plc, Beijing Tiantan Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd, Zydus Cadila Healthcare Limited, Sinovac Biotech Ltd., Prometheon Pharma, LLC, Organic Vaccines and China National Pharmaceutical Group Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Mumps Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Mumps Drug Market by Company
GlaxoSmithKline Plc
Beijing Tiantan Biological Products Co., Ltd.
Beijing Minhai Biotechnology Co., Ltd
Zydus Cadila Healthcare Limited
Sinovac Biotech Ltd.
Prometheon Pharma, LLC
Organic Vaccines
China National Pharmaceutical Group Corporation
Mumps Drug Segment by Type
RIT 4385
Wistar RA 27/3
Schwarz
Others
Mumps Drug Segment by Application
Hospital
Clinic
Others
Mumps Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mumps Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mumps Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mumps Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Mumps Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Mumps Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Mumps Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- RIT 4385
- Wistar RA 27/3
- Schwarz
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- GlaxoSmithKline Plc
- Beijing Tiantan Biological Products Co., Ltd.
- Beijing Minhai Biotechnology Co., Ltd
- Zydus Cadila Healthcare Limited
- Sinovac Biotech Ltd.
- Prometheon Pharma, LLC
- Organic Vaccines
- China National Pharmaceutical Group Corporation
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Mumps Drug Market Size (2021-2032)
- 2.2.2 Global Mumps Drug Sales (2021-2032)
- 2.2.3 Global Mumps Drug Market Average Price (2021-2032)
- 2.3 Mumps Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 RIT 4385
- 2.3.3 Wistar RA 27/3
- 2.3.4 Schwarz
- 2.3.5 Others
- 2.4 Mumps Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Mumps Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Mumps Drug Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Mumps Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Mumps Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Mumps Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Mumps Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Mumps Drug, Product Type & Application
- 3.8 Global Manufacturers of Mumps Drug, Established Date
- 3.9 Global Mumps Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GlaxoSmithKline Plc
- 4.1.1 GlaxoSmithKline Plc Company Information
- 4.1.2 GlaxoSmithKline Plc Business Overview
- 4.1.3 GlaxoSmithKline Plc Mumps Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GlaxoSmithKline Plc Mumps Drug Product Portfolio
- 4.1.5 GlaxoSmithKline Plc Recent Developments
- 4.2 Beijing Tiantan Biological Products Co., Ltd.
- 4.2.1 Beijing Tiantan Biological Products Co., Ltd. Company Information
- 4.2.2 Beijing Tiantan Biological Products Co., Ltd. Business Overview
- 4.2.3 Beijing Tiantan Biological Products Co., Ltd. Mumps Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Beijing Tiantan Biological Products Co., Ltd. Mumps Drug Product Portfolio
- 4.2.5 Beijing Tiantan Biological Products Co., Ltd. Recent Developments
- 4.3 Beijing Minhai Biotechnology Co., Ltd
- 4.3.1 Beijing Minhai Biotechnology Co., Ltd Company Information
- 4.3.2 Beijing Minhai Biotechnology Co., Ltd Business Overview
- 4.3.3 Beijing Minhai Biotechnology Co., Ltd Mumps Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Beijing Minhai Biotechnology Co., Ltd Mumps Drug Product Portfolio
- 4.3.5 Beijing Minhai Biotechnology Co., Ltd Recent Developments
- 4.4 Zydus Cadila Healthcare Limited
- 4.4.1 Zydus Cadila Healthcare Limited Company Information
- 4.4.2 Zydus Cadila Healthcare Limited Business Overview
- 4.4.3 Zydus Cadila Healthcare Limited Mumps Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Zydus Cadila Healthcare Limited Mumps Drug Product Portfolio
- 4.4.5 Zydus Cadila Healthcare Limited Recent Developments
- 4.5 Sinovac Biotech Ltd.
- 4.5.1 Sinovac Biotech Ltd. Company Information
- 4.5.2 Sinovac Biotech Ltd. Business Overview
- 4.5.3 Sinovac Biotech Ltd. Mumps Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sinovac Biotech Ltd. Mumps Drug Product Portfolio
- 4.5.5 Sinovac Biotech Ltd. Recent Developments
- 4.6 Prometheon Pharma, LLC
- 4.6.1 Prometheon Pharma, LLC Company Information
- 4.6.2 Prometheon Pharma, LLC Business Overview
- 4.6.3 Prometheon Pharma, LLC Mumps Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Prometheon Pharma, LLC Mumps Drug Product Portfolio
- 4.6.5 Prometheon Pharma, LLC Recent Developments
- 4.7 Organic Vaccines
- 4.7.1 Organic Vaccines Company Information
- 4.7.2 Organic Vaccines Business Overview
- 4.7.3 Organic Vaccines Mumps Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Organic Vaccines Mumps Drug Product Portfolio
- 4.7.5 Organic Vaccines Recent Developments
- 4.8 China National Pharmaceutical Group Corporation
- 4.8.1 China National Pharmaceutical Group Corporation Company Information
- 4.8.2 China National Pharmaceutical Group Corporation Business Overview
- 4.8.3 China National Pharmaceutical Group Corporation Mumps Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 China National Pharmaceutical Group Corporation Mumps Drug Product Portfolio
- 4.8.5 China National Pharmaceutical Group Corporation Recent Developments
5 Global Mumps Drug Market Scenario by Region
- 5.1 Global Mumps Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Mumps Drug Sales by Region: 2021-2032
- 5.2.1 Global Mumps Drug Sales by Region: 2021-2026
- 5.2.2 Global Mumps Drug Sales by Region: 2027-2032
- 5.3 Global Mumps Drug Revenue by Region: 2021-2032
- 5.3.1 Global Mumps Drug Revenue by Region: 2021-2026
- 5.3.2 Global Mumps Drug Revenue by Region: 2027-2032
- 5.4 North America Mumps Drug Market Facts & Figures by Country
- 5.4.1 North America Mumps Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Mumps Drug Sales by Country (2021-2032)
- 5.4.3 North America Mumps Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Mumps Drug Market Facts & Figures by Country
- 5.5.1 Europe Mumps Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Mumps Drug Sales by Country (2021-2032)
- 5.5.3 Europe Mumps Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Mumps Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Mumps Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Mumps Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Mumps Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Mumps Drug Market Facts & Figures by Country
- 5.7.1 South America Mumps Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Mumps Drug Sales by Country (2021-2032)
- 5.7.3 South America Mumps Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Mumps Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Mumps Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Mumps Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Mumps Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Mumps Drug Sales by Type (2021-2032)
- 6.1.1 Global Mumps Drug Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Mumps Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Mumps Drug Revenue by Type (2021-2032)
- 6.2.1 Global Mumps Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Mumps Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Mumps Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Mumps Drug Sales by Application (2021-2032)
- 7.1.1 Global Mumps Drug Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Mumps Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Mumps Drug Revenue by Application (2021-2032)
- 7.2.1 Global Mumps Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Mumps Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Mumps Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Mumps Drug Value Chain Analysis
- 8.1.1 Mumps Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Mumps Drug Production Mode & Process
- 8.2 Mumps Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Mumps Drug Distributors
- 8.2.3 Mumps Drug Customers
9 Global Mumps Drug Analyzing Market Dynamics
- 9.1 Mumps Drug Industry Trends
- 9.2 Mumps Drug Industry Drivers
- 9.3 Mumps Drug Industry Opportunities and Challenges
- 9.4 Mumps Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst